News Website

Dr Corr on the Rationale for Investigating Rucaparib Maintenance in Endometrial Cancer - OncLive

Dr Corr on the Rationale for Investigating Rucaparib Maintenance in Endometrial Cancer OncLive

Published: May 10, 2024, 7 a.m.

Read Full Article

Merck's endometrial cancer therapy fails trial - Reuters

Merck's endometrial cancer therapy fails trial Reuters

Published: May 9, 2024, 7 a.m.

Read Full Article

Postsurgical Pembrolizumab and Chemo, With or Without Radiotherapy, Falls Short in Phase 3 Trial for Newly Diagnosed, High-Risk Endometrial Cancer - AJMC.com Managed Markets Network

Postsurgical Pembrolizumab and Chemo, With or Without Radiotherapy, Falls Short in Phase 3 Trial for Newly Diagnosed, High-Risk Endometrial Cancer AJMC.com Managed Markets Network

Published: May 9, 2024, 7 a.m.

Read Full Article

Merck's Keytruda plus chemo comes up short as post-surgery therapy in newly diagnosed endometrial cancer - FiercePharma

Merck's Keytruda plus chemo comes up short as post-surgery therapy in newly diagnosed endometrial cancer FiercePharma

Published: May 9, 2024, 7 a.m.

Read Full Article

Phase 3 trial evaluating Keytruda in endometrial cancer misses primary survival endpoint - Healio

Phase 3 trial evaluating Keytruda in endometrial cancer misses primary survival endpoint Healio

Published: May 9, 2024, 7 a.m.

Read Full Article

Keytruda Strikes Out Again in Endometrial Cancer with Phase III Flop - BioSpace

Keytruda Strikes Out Again in Endometrial Cancer with Phase III Flop BioSpace

Published: May 9, 2024, 7 a.m.

Read Full Article

Merck's endometrial cancer therapy fails trial - ETHealthWorld

Merck's endometrial cancer therapy fails trial ETHealthWorld

Published: May 9, 2024, 7 a.m.

Read Full Article

After an Endometrial Cancer Diagnosis, A Nurse Seizes a Chance to Soar - Health Matters

After an Endometrial Cancer Diagnosis, A Nurse Seizes a Chance to Soar Health Matters

Published: May 3, 2024, 7 a.m.

Read Full Article

Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials - The Lancet

Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials The Lancet

Published: April 30, 2024, 7 a.m.

Read Full Article

Combining the prognostic role of age with molecular advances in the understanding of endometrial cancer - The Lancet

Combining the prognostic role of age with molecular advances in the understanding of endometrial cancer The Lancet

Published: April 30, 2024, 7 a.m.

Read Full Article

Latest Articles

Dr Corr on the Rationale for Investigating Rucaparib Maintenance in Endometrial Cancer - OncLive

Merck's endometrial cancer therapy fails trial - Reuters

Postsurgical Pembrolizumab and Chemo, With or Without Radiotherapy, Falls Short in Phase 3 Trial for Newly Diagnosed, High-Risk Endometrial Cancer - AJMC.com Managed Markets Network

Merck's Keytruda plus chemo comes up short as post-surgery therapy in newly diagnosed endometrial cancer - FiercePharma

Phase 3 trial evaluating Keytruda in endometrial cancer misses primary survival endpoint - Healio

Keytruda Strikes Out Again in Endometrial Cancer with Phase III Flop - BioSpace

Merck's endometrial cancer therapy fails trial - ETHealthWorld

After an Endometrial Cancer Diagnosis, A Nurse Seizes a Chance to Soar - Health Matters

Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials - The Lancet

Combining the prognostic role of age with molecular advances in the understanding of endometrial cancer - The Lancet

Subscribe to Our Newsletter